ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

NEXT STORY
TLC Reports Third Quarter 2019 Financial Results and Provides Business Update
PREV STORY
Novartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USA
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting

author_avatar
NASDAQ Market News

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

author_avatar
NASDAQ Market News

Handheld DNA Analyzer Market Is Projected To Witness The Fastest Growth In Asia-Pacific Region During Forthcoming Years 2020-2027: Acumen Research And Consulting

author_avatar
NASDAQ Market News